stockrowSmith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Return on assets
Smith & Nephew SNATS, Inc.'s return on assets over the twelve months to 30 June 2026 was 0.00%, down 6.0 percentage points from fiscal 2025 (6.01%). Over the past ten years it has ranged from 2.14% (fiscal 2022) to 10.8% (fiscal 2016); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 6.01% | 1.96 |
| FY2024 | 4.05% | 1.41 |
| FY2023 | 2.64% | 0.50 |
| FY2022 | 2.14% | (2.64) |
| FY2021 | 4.78% | 0.37 |
| FY2020 | 4.41% | (2.50) |
| FY2019 | 6.91% | (1.42) |
| FY2018 | 8.33% | (1.76) |
| FY2017 | 10.1% | (0.72) |
| FY2016 | 10.8% | 5.14 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PODD Insulet Corporation compare | 13.3% |
| GMED Globus Medical, Inc. compare | 10.5% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 9.99% |
| BIO Bio-Rad Laboratories, Inc. compare | 9.99% |
| PEN Penumbra, Inc. compare | 8.33% |
| SNN Smith & Nephew SNATS, Inc. | 0.00% |
| BRKR Bruker Corporation compare | −2.73% |
| TXG 10x Genomics compare | −7.47% |
| GKOS Glaukos Corporation compare | −17.2% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement